Your browser doesn't support javascript.
Шоу: 20 | 50 | 100
Результаты 1 - 3 de 3
Фильтр
Добавить фильтры

база данных
Годовой диапазон
1.
J Integr Complement Med ; 2022 Oct 26.
Статья в английский | MEDLINE | ID: covidwho-2227084
2.
Mol Neurobiol ; 58(8): 4178-4187, 2021 Aug.
Статья в английский | MEDLINE | ID: covidwho-1274943

Реферат

The coronavirus disease that presumably began in 2019 (COVID-19) is a highly infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic. Initially, COVID-19 was thought to only affect respiration. However, accumulating evidence shows a wide range of neurological symptoms are also associated with COVID-19, such as anosmia/ageusia, headaches, seizures, demyelination, mental confusion, delirium, and coma. Neurological symptoms in COVID-19 patients may arise due to a cytokine storm and a heighten state of inflammation. The nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) is a central pathway involved with inflammation and is shown to be elevated in a dose-dependent matter in response to coronaviruses. NF-κB has a role in cytokine storm syndrome, which is associated with greater severity in COVID-19-related symptoms. Therefore, therapeutics that reduce the NF-κB pathway should be considered in the treatment of COVID-19. Neuro-COVID-19 units have been established across the world to examine the neurological symptoms associated with COVID-19. Neuro-COVID-19 is increasingly becoming an accepted term among scientists and clinicians, and interdisciplinary teams should be created to implement strategies for treating the wide range of neurological symptoms observed in COVID-19 patients.


Тема - темы
COVID-19/complications , COVID-19/metabolism , NF-kappa B/metabolism , Nervous System Diseases/virology , SARS-CoV-2/physiology , Brain/pathology , Brain/virology , COVID-19/virology , Humans , Inflammation/pathology , COVID-19 Drug Treatment
3.
J Alzheimers Dis ; 81(2): 427-450, 2021.
Статья в английский | MEDLINE | ID: covidwho-1170069

Реферат

Persons with dementia (PWD) make up a large portion of the long-term care (LTC) population the world over. Before a global pandemic swept the world, governments and healthcare providers struggled with how to best care for this unique population. One of the greatest challenges is a PWD's tendency to "walk with purpose" and exhibit unsafe wayfinding and elopement, which places them at risk of falls and injury. Past solutions included increased use of restraints and pharmacological interventions, but these have fallen out of favor over the years and are not optimal. These challenges put enormous strain on staff and caregivers, who are often poorly trained in dementia care, underpaid, overworked, and overstressed. PWD are impacted by these stresses, and unmet needs in LTC places an even greater stress on them and increases their risks of morbidity and mortality. The physical design of their environments contributes to the problem. Old, institutionalized buildings have poor lighting, poor ventilation, long dead-end hallways, poor visual cues, lack of home-like décor, shared bedrooms and bathrooms, and are often dense and overcrowded. These design elements contribute to the four 'A's' of dementia: apathy, anxiety, agitation, and aggression, and they also contributed to the rapid spread of COVID-19 in these facilities the world over. In this review, we present current "dementia friendly" design models in the home, community, and LTC, and argue how they could have saved lives during the pandemic and reduced the stresses on both the dementia resident and the caregiver/staff.


Тема - темы
Dementia/therapy , Environment Design , Health Services Needs and Demand , Long-Term Care , Quality of Life , COVID-19 , Humans , Pandemics
Критерии поиска